Waxman/Hatch Reform May Include Generic Exclusivity, PhRMA Warns GPhA
Executive Summary
The Pharmaceutical Research & Manufacturers of America may encourage discussions on whether 180-day generic exclusivity should be abolished if Congress reopens Waxman/Hatch
You may also be interested in...
Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings
A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
The generic industry should consider carefully any attempt to derail FDA's regulatory approach to Waxman/Hatch reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association
GSK Supports Waxman/Hatch Trade: Drop Bolar, Remove 30-Month Stays
GlaxoSmithKline supports a legislative deal to change the 30-month stays on generic approvals during patent litigation in return for having generic firms give up their right to do development work on drugs prior to patent expiration